In a bid to keep its business afloat into 2027, Korro Bio is streamlining its operations, a move that will involve a 20% workforce reduction, the biotech announced Wednesday alongside its Q1 business report. The layoffs, which will cost Korro $1.2 million in one-time payments, will help the biotech advance its assets to “key value inflection points.” In particular, Korro aims to complete its ongoing Phase I/IIa REWRITE trial, which is testing its investigational RNA-editing oligonucleotide KRRO-110 in alpha-1 antitrypsin deficiency. The company expects to wrap up REWRITE in 2026.